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Purpose: Antimuscarinic therapy remains one of the most common forms of therapy 
for overactive bladder (OAB) in children. However, few clinical studies on the outcomes 
of antimuscarinics in children with OAB have been published. Therefore, we evaluated 
the efficacy and safety of propiverine, which is frequently prescribed for the treatment 
of pediatric OAB.
Materials and Methods: We retrospectively reviewed children with OAB treated with 
propiverine within the past 5 years. The response rates were compared between the 
non-urge incontinence (non-UI) and urge incontinence (UI groups). The cumulative re-
sponse rate by treatment duration was also compared between the two groups. 
Results: Among a total of 68 children, 50 children (73.5%) experienced UI. The overall 
response rate was 86.8%. Functional bladder capacity after treatment was 150 ml, 
which represented an increase compared with the value (140 ml) before treatment. The 
voiding frequency per day decreased from 14.0 to 8.5 times. The overall response rate 
(88.0%) in the non-UI group was not significantly different from that seen in the UI 
group (83.3%; p＞0.05). In non-UI children, the cumulative response rates were 36.0%, 
54.0%, 68.0%, 74.0%, 76.0%, and 78.0% at 4, 8, 12, 16, 20, and 24 weeks, respectively. 
The cumulative response rates in the UI children were 11.1%, 33.3%, 44.4%, 50.0%, 
50.0%, and 55.6%, respectively during the same respective time periods. Adverse effects 
were identified in only two (2.9%) patients, and neither case was severe.
Conclusions: Propiverine is effective and well tolerated as a treatment for children suf-
fering from OAB with or without UI.
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INTRODUCTION
Overactive bladder (OAB) is relatively common in child-
ren. Although urotherapy, including lifestyle modifica-
tions, is recommended initially, antimuscarinic medi-
cation remains one of the most common forms of therapy 
for OAB in children. Although various antimuscarinic 
drugs have been introduced and are widely used with pro-
ven efficacy and stability in adult OAB patients, not all an-
timuscarinic drugs are suitable for children.
Oxybutynin chloride is the only antimuscarinic drug li-
censed for use in pediatric patients by the Food and Drug 
Administration in the United States. Most clinicians have 
prescribed oxybutynin for pediatric OAB patients. Howev-
er, oxybutynin is now available in an extended-release tab-
let form, which is superior to the previous immedi-
ate-release tablet form but is still not recommended for in-
fants and toddlers.
Propiverine, an antimuscarinic drug widely used in 
adult OAB patients, is popular in pediatric patients as well Korean J Urol 2012;53:275-279
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TABLE 1. Demographic characteristics and baseline parameters of the patients
Variable Total Non-UI UI p-value
No. of patients
Age at the time of treatment start (yr)
Gender
    Male
    Female
Baseline values
    Median voiding frequency (d)
    Median functional bladder capacity (ml)
Associated symptom
    Enuresis
    Constipation
Daily dosage
    10 mg
    20 mg
Treatment duration (wk)
68 (100)
5.9 (3.1-10.0)
37 (54.4)
31 (45.6)
14.0 (8.0-72.0)
140 (30-300)
17 (25.0)
4 (5.9)
25 (36.8)
43 (63.2)
7.5 (2.0-66.0)
50 (73.5)
5.8 (3.1-10.0)
30 (60.0)
20 (40.0)
14.0 (8.0-72.0)
140 (30-300)
8 (16.0)
2 (4.0)
18 (36.0)
32 (64.0)
13.5 (3.0-66.0)
18 (26.5)
6.3 (3.2-9.7)
7 (38.9)
11 (61.1)
9.8 (8.0-23.0)
110 (30-220)
9 (50.0)
2 (11.1)
7 (38.8)
11 (61.1)
5.5 (2.0-51.0)
0.439
0.123
0.667
0.209
0.004
0.272
0.827
0.024
Values are presented as median (range) or number (%).
UI, urge incontinence.
because it can be easily ground into a powdered form. In 
practice, propiverine could be easily administered to OAB 
children with better drug compliance. However, few clin-
ical studies about the outcomes of propiverine in children 
with OAB have been reported. In the present study, there-
fore, we evaluated the efficacy and safety of propiverine.
MATERIALS AND METHODS
Children with OAB who were treated with propiverine 
from October 2006 to February 2011 in Samsung Medical 
Center were retrospectively reviewed. This research proto-
col was approved by the Samsung Medical Center Institu-
tional Review Board. A detailed history, including a lower 
urinary tract symptom (LUTS) questionnaire [1], physical 
examination, and 3-day frequency volume chart, was ob-
tained from each patient. Urinalysis and uroflowmetry 
with residual urine check were also performed for each 
patient. Only children who received the drug for at least 2 
weeks and who had evaluable pre- and post-treatment fre-
quency volume charts were included in this study. Any chil-
dren with neuropathic bladder, spinal dysraphism, ana-
tomical abnormalities (e.g., posterior urethral valves or 
vesicoureteral reflux), or suspected urinary tract in-
fections were excluded.
The efficacy of propiverine was measured on the basis of 
improvement of OAB symptoms (frequency, urgency, and 
urge incontinence), change of voiding frequency, and max-
imum voided volume. The symptom improvement data af-
ter propiverine treatment were classified into the following 
three categories: nonresponse (0 to 49% decrease of symp-
toms), partial response (50 to 99% decrease of symptoms), 
and full response (100% decrease of symptoms). Any ad-
verse effects related to treatment were recorded. 
Patients were divided into the non-urge incontinence 
(non-UI) and urge incontinence (UI) groups according to 
their symptom severity. The response rate was compared 
between the non-UI and UI groups. The cumulative re-
sponse rates by treatment duration were also compared be-
tween the two groups. 
To evaluate differences in treatment success between 
groups, we used the Pearson chi-square test. Data were an-
alyzed by using SPSS ver. 18.0 (SPSS Inc., Chicago, IL, 
USA). Probability values less than 0.05 were considered to 
be statistically significant.
RESULTS
During the study period, 68 children (37 male, 31 female) 
with a median age of 5.9 years (range, 3.1 to 10.0 years) sat-
isfied the inclusion criteria. Eighteen patients (26.5%) had 
UI, 17 patients (25.0%) experienced nocturnal enuresis, 
and 4 patients (5.9%) had constipation at treatment entry. 
Median voiding frequency was 14 times per day (range, 8 
to 72 times), and the median functional bladder capacity 
was 140 ml (range, 30 to 300 ml). The median treatment 
duration was 7.5 weeks (range, 2 to 66 weeks), and the pro-
piverine dosage at the end of the treatment period was 10 
mg for 25 children (36.8%) and 20 mg for 43 children (63.2%) 
(Table 1). 
The median voiding frequency during the daytime de-
creased from 14.0 to 8.5, and median functional bladder ca-
pacity changed from 140 to 150 ml (Fig. 1). The overall re-
sponse rate after propiverine treatment was 86.8% in all 
the children. The response rate was higher in the non-UI 
group (88.0%) than in the UI group (83.3%), but the differ-
ence was not statistically significant (p＞0.05) (Fig. 2).
The symptom improvement rate increased with treat-
ment duration. In non-UI children, the cumulative re-
sponse rates were 36.0%, 54.0%, 68.0%, 74.0%, 76.0%, and 
78.0% at 4, 8, 12, 16, 20, and 24 weeks, respectively. The 
cumulative response rates in UI children were 11.1%, Korean J Urol 2012;53:275-279
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FIG. 1. Changes in voiding frequency and maximum voided volume after propiverine treatment. (A) Change in voiding frequency. (B) 
Change in functional bladder capacity. UI, urge incontinence.
FIG. 2. Symptom improvement rate of propiverine treatment. 
Nonresponse, 0 to 49% decrease; Partial response, 50 to 99% 
decrease; Full response, 100% decrease in incontinence or less 
than 1 incontinence incident monthly. UI, urge incontinence.
FIG. 3. Symptom improvement rate of treatment with respect to 
duration of treatment. UI, urge incontinence.
TABLE 2. Adverse effects
Adverse effect No. (%)
Constipation
Dryness of the mouth
Dizziness
Headache
Nausea
Hot flush
Visual disturbance
Abdominal pain
Total
1 (1.5)
1 (1.5)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (2.9)
33.3%, 44.4%, 50.0%, 50.0%, and 55.6%, respectively, dur-
ing the same period (Fig. 3). Adverse effects were identified 
in only two patients (2.9%), and neither case was severe 
(one case of dry mouth and one of constipation) (Table 2).
DISCUSSION
OAB is frequently seen in childhood. The incidence of OAB 
in school-aged children ranges from 17.8 to 26% [2-4]. In 
a recent study, the incidence of pediatric OAB in South 
Korea was 16.6% in children aged 5 to 13 years [5]. 
The etiology of OAB is not completely understood. The 
prevailing theory of pediatric OAB is a delay in the acquis-
ition of cortical inhibition over uninhibited detrusor 
contractions. In general, it is believed that the maturation 
period for cortical control of voiding function is between 3 
and 5 years of age, and the completion period for fine-tuning 
of the detrusor muscle is about 8 years [6]. The sites of ma-
turational delay are thought to be the reticulospinal path-
ways of the spinal cord or the inhibitory center of the cere-
bral cortex [7]. Children with OAB might have difficulty 
achieving the mature voiding patterns that are character-
istic of adulthood. Inflammatory processes in the bladder 
wall are also thought to be an etiology of pediatric OAB. Korean J Urol 2012;53:275-279
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Such inflammation can also irritate receptors in the sub-
mucosal and detrusor muscle layers and lead to LUTS [8].
Children with idiopathic OAB are initially treated with 
urotherapy; a nonsurgical, nonpharmacological treatment 
consisting of lower urinary tract rehabilitation using regu-
lar voiding with drinking and voiding charts, lifestyle 
changes, and some specific interventions such as physi-
otherapy, alarm therapy, and neurostimulation [9]. When 
urotherapy fails, antimuscarinic drugs can be used. For 
adult OAB patients, various antimuscarinic drugs such as 
oxybutynin, propiverine, tolterodine, trospium chloride, 
and solifenacin have been introduced and are widely used 
with proven efficacy and stability [10-14]. In contrast, oxy-
butynin chloride is the only FDA-approved antimuscarinic 
drug licensed for use in pediatric patients [15]. Currently, 
oxybutynin extended release (ER) rather than oxybutynin 
immediate release (IR) is widely administered in South 
Korea. Oxybutynin ER is superior to oxybutynin IR with 
regard to adverse effects; however, it is only available in 
tablet form, which is difficult for infants and toddlers to 
swallow. OAB children might show better drug compliance 
when treated with propiverine hydrochloride than oxy-
butynin because propiverine can be easily ground into a 
powdered form, whereas oxybutynin ER tablets cannot be 
broken [16]. In addition, a previous comparative study of 
propiverine and oxybutynin in children revealed lower ad-
verse drug reaction rates for propiverine than oxybutynin 
[17]. Therefore, it is very important that clinicians under-
stand the efficacy and safety of this drug, which inevitably 
could be used in clinical practice. Our study is meaningful 
because it is the first report of the efficacy and safety of pro-
piverine in East Asian children. Recently, a randomized 
placebo-controlled clinical trial reported objective efficacy 
and good tolerability of propiverine [18]. Although that 
study was a well-designed randomized controlled study, it 
did not cover the differences in clinical outcomes according 
to the symptom severity of the OAB children. Our study is 
a comparative one of the efficacy of propiverine for symp-
tom severity. 
We found that propiverine therapy leads to a significant 
increase in functional bladder capacity and a decrease in 
voiding frequency. The drug also dramatically improved 
LUTS in OAB children; the overall response rate was 86.8% 
for the total treatment group. A previous study reported the 
overall efficacy of propiverine in OAB children to be 86.8%, 
and we found similar results in our study [17]. Propiverine 
is thought to act on the bladder via dual modes of action. 
Antimuscarinic agents cause parallel shifts to the right of 
the concentration-response curves to acetylcholine. In ad-
dition to this antagonistic muscarinic effect, which it 
shares with other antimuscarinic agents, propiverine 
causes a concentration-dependent inhibition of the KCl- 
and CaCl2-induced contractions [19].
Clinical practitioners have often encountered the prob-
lem of how long to prescribe anticholinergic drugs. 
According to our results, treatment should last for at least 
8 weeks to achieve a response rate of 50%. For children with 
UI, the treatment period was longer than for those in the 
non-UI group. The response rate after 8 weeks of treatment 
was 54.0% for the non-UI group, 33.3% for the UI group, 
and 48.5% for the overall treatment group. To the best of 
our knowledge, this study was the first to evaluate the cu-
mulative response rate of propiverine for OAB children 
without UI; it is also the first study that compared non-UI 
and UI groups. We believe that our results will provide ad-
vantageous information about propiverine for pediatric 
use in clinical practice.
Adverse effects were reported in only two patients, and 
neither case experienced severe symptoms. This finding 
supports previous clinical reports that children experience 
adverse effects (such as dry mouth or visual disturbances) 
less frequently than do adults when treated with propiver-
ine [19]. Our data showed lower adverse events than did 
previous studies that reported adverse effect rates after an-
ticholinergics treatment in OAB children [15-19]. Several 
hypotheses are possible to explain this difference. Propi-
verine might act specifically on the bladder in children; 
therefore, extravesical adverse effects are minimal. The 
other hypothesis is that children cannot easily express the 
symptoms of adverse reactions; thus, these might be 
underreported. 
Our study had several limitations. First, it was an uncon-
trolled retrospective study, and we evaluated the efficacy 
of therapy by using frequency volume charts and sub-
jectively described improvements alone. The potential for 
bias also existed in the patient selection because we in-
cluded only children with relatively good drug compliance. 
The second limitation of our study was that most of our pa-
tients received medication therapy not by itself but com-
bined with standard urotherapy. The improvement in OAB 
symptoms might be partially a result of the standard 
urotherapy. Despite these limitations, however, our study 
results contain important and practical information for an-
timuscarinic drug treatment, especially propiverine, in 
children with OAB.
CONCLUSIONS
Propiverine has good efficacy and is well tolerated as a 
treatment for children suffering from OAB with or without 
UI. At least 9 weeks of treatment are needed to achieve a 
response rate of 50%. For children with UI, the treatment 
period was longer than for children without UI. 
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